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Abstract
Inter-individual variation in gene regulatory elements is hypothesized to play a causative role in adverse drug reactions and
reduced drug activity. However, relatively little is known about the location and function of drug-dependent elements. To
uncover drug-associated elements in a genome-wide manner, we performed RNA-seq and ChIP-seq using antibodies
against the pregnane X receptor (PXR) and three active regulatory marks (p300, H3K4me1, H3K27ac) on primary human
hepatocytes treated with rifampin or vehicle control. Rifampin and PXR were chosen since they are part of the CYP3A4
pathway, which is known to account for the metabolism of more than 50% of all prescribed drugs. We selected 227
proximal promoters for genes with rifampin-dependent expression or nearby PXR/p300 occupancy sites and assayed their
ability to induce luciferase in rifampin-treated HepG2 cells, finding only 10 (4.4%) that exhibited drug-dependent activity. As
this result suggested a role for distal enhancer modules, we searched more broadly to identify 1,297 genomic regions
bearing a conditional PXR occupancy as well as all three active regulatory marks. These regions are enriched near genes that
function in the metabolism of xenobiotics, specifically members of the cytochrome P450 family. We performed enhancer
assays in rifampin-treated HepG2 cells for 42 of these sequences as well as 7 sequences that overlap linkage-disequilibrium
blocks defined by lead SNPs from pharmacogenomic GWAS studies, revealing 15/42 and 4/7 to be functional enhancers,
respectively. A common African haplotype in one of these enhancers in the GSTA locus was found to exhibit potential
rifampin hypersensitivity. Combined, our results further suggest that enhancers are the predominant targets of rifampin-
induced PXR activation, provide a genome-wide catalog of PXR targets and serve as a model for the identification of drug-
responsive regulatory elements.
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Introduction
Adverse reactions to drug treatment constitute a substantial
health problem that is a leading cause of morbidity and mortality
in hospitalized patients [1]. Differential expression of drug
metabolizing enzymes and drug transporters is a major determi-
nant of inter-individual drug response variability [2–5]. By
sequestering and metabolizing drug compounds in the liver and
intestine, these enzymes and transporters effectively determine
whether target organs and tissues are exposed to optimal drug
dosages. Several coding mutations in these proteins have been
detected which lead to adverse outcomes [6–10] and reduced drug
activity [11,12]. Regulatory elements, including promoters and
enhancers, also likely play an important role that has so far been
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largely uncharacterized [13,14]. The systematic identification of
drug-responsive regulatory elements would thus provide a unique
resource to discover novel genetic variants that lead to differences
in drug response.
The vast majority of pharmaceutical compounds are metabo-
lized by the cytochrome P450 family (CYP) of enzymes. Of these,
CYP3A4 is the most abundantly expressed in sites of drug
disposition in the liver [15] and is also thought to be responsible
for the metabolism of at least 50% of prescribed pharmaceuticals
[16]. CYP3A4 activity can vary 5–20 fold between individuals [17]
and its mRNA expression can vary as much as 120 fold [18]. Only
a few single nucleotide polymorphisms (SNPs) in the immediate
CYP3A4 locus have been found to be associated with CYP3A4
hepatic expression [19–21], suggesting that its variable expression
could be caused by other genes and distant regulatory elements.
CYP3A4 is one of many targets of the nuclear receptor PXR
(coded by NR1I2), which is expressed predominantly in the liver
and intestine [22] and is essential for activating Phase I and II
enzymes in response to xenobiotics. PXR’s broad substrate
specificity allows it to be activated by a wide variety of drugs
including the antibiotic rifampin, the malaria resistance drug
artemisinin, the hypolipidemic agent mevastatin, and the chemo-
therapeutic agent paclitaxel [2]. Relatively little is known about
the mechanism by which PXR drives CYP3A4 transcription in
vivo, although PXR response elements have been identified in the
putative CYP3A4 promoter [23] and upstream cis-regulatory
elements [24,25] that drive its expression in vitro. Additional PXR
responsive enhancers have been found for other CYPs [26,27].
Chromatin immunoprecipitation followed by sequencing (ChIP-
seq) of PXR-bound DNA elements in livers from mice treated with
PCN (a mouse PXR agonist) identified .3,000 drug-induced
binding sites [28]. ChIP-seq for other drug-associated transcription
factors such as LXR, RXR and PPARA has also been carried out
in mouse liver [29]. However, the inherent drug metabolism
differences between mouse and humans, in particular for PXR
and the mouse homolog of CYP3A4 [22,30,31], hinder the ability
to directly translate these results to humans.
To identify PXR-associated regulatory elements in a genome-
wide manner, we carried out RNA sequencing (RNA-seq) and
ChIP-seq with antibodies for PXR and three different enhancer
marks on primary human hepatocytes treated with rifampin or
vehicle control. These included the E1A binding protein p300
(EP300/p300) which has been used to identify functional
enhancers in vivo with high success rates [32], and two histone
marks, H3K4me1 and H3K27ac. H3K4me1 marks both poised
and active regulatory regions [33] while H3K27ac was shown to
selectively mark active regions [34,35]. We identified thousands of
sequences that had rifampin induced ChIP-seq peaks. A reporter
validation screen of proximal promoters associated with these
peaks yielded only a few functional rifampin-dependent sequences.
A similar assay for distal enhancers resulted in the identification of
several novel drug-dependent enhancers. Analyses of nucleotide
variants in selected sequences found a common African haplotype
in the GSTA locus to possibly affect rifampin sensitivity.
Results
We acquired induction-qualified cryopreserved human hepa-
tocytes originating from a single male donor (see Methods). To
verify their inducibility, we treated cultured cells with 10 mM
rifampin or DMSO control for 24 hours and then carried out
quantitative PCR (qPCR) for 84 genes involved in Phase I
metabolism (Table S1). Rifampin was used to activate PXR
because of the wide body of literature on this interaction [36].
Furthermore, the FDA recommends using rifampin for in vitro
and in vivo enzyme and transporter induction studies during
drug development (http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/ucm29
2362.pdf). Ten genes were induced greater than two-fold
(CYP3A4, CYP3A43, CYP3A7, CYP2C8, CYP2A13, CYP2C9,
CYP24A1, CYP1A1, CYP2B6, CYP3A5) and only one was
downregulated (CYP26B1). CYP3A4 was by far the most
differentially expressed gene with a .1,000 fold induction (.10
PCR cycles difference), followed by the other members of the
CYP3A family (Table S1). These results indicated that this lot of
cryopreserved human hepatocytes was highly inducible by
rifampin, making it suitable for subsequent RNA-seq and
ChIP-seq assays.
To identify PXR-associated regulatory elements in a genome-
wide manner, we performed ChIP-seq on rifampin and DMSO-
treated hepatocytes using antibodies for PXR and three enhancer
marks (p300, H3K27ac, H3K4me1) (Figure 1A). The resulting
libraries from these samples were sequenced along with a
chromatin input sample that was used as a reference for peak
calling. In addition, we collected total RNA for each treatment
and carried out RNA-seq to acquire a broader view of rifampin-
induced gene expression changes. To increase our reproducibility,
we combined our RNA-seq results with a previously reported
RNA-seq dataset for rifampin treated and non-treated human
hepatocytes from seven different individuals [37] (see methods).
Drug-associated genes are differentially expressed upon
rifampin treatment
Our RNA-seq analyses found several differentially expressed
genes, the majority of which are known to be involved in drug
response. The number of differentially expressed genes using a p-
value cutoff, after adjustment for multiple testing less than or equal
to 0.05, was 157 (Table S1). Amongst them, 11 were CYPs, with
the top differentially expressed gene being CYP3A4, similar to our
qPCR results. Of the eleven differentially expressed genes
identified by qPCR, seven (64%) were also found to be
differentially expressed by RNA-seq. It is worth noting that two
(CYP2C9, CYP2C19) of the four genes that didn’t replicate in the
RNA-seq data, showed a non-statistically significant induction by
rifampin in our RNA-seq.
Author Summary
Drug response varies between individuals and can be
caused by genetic factors. Nucleotide variation in gene
regulatory elements can have a significant effect on drug
response, but due to the difficulty in identifying these
elements, they remain understudied. Here, we used
various genomic assays to analyze human liver cells
treated with or without the antibiotic rifampin and
identified drug-induced regulatory elements genome-
wide. The testing of numerous active promoters in human
liver cells showed only a few to be induced by rifampin
treatment. A similar analysis of enhancers found several of
them to be induced by the drug. Nucleotide variants in
one of these enhancers were found to alter its activity.
Combined, this work identifies numerous novel gene
regulatory elements that can be activated due to drug
response and thus provides candidate sequences in the
human genome where nucleotide variation can lead to
differences in drug response. It also provides a universally
applicable method to detect these elements for other
drugs.
Drug-Dependent Liver Enhancers
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Rifampin drives PXR and p300 recruitment at putative
regulatory elements
We observed a massive recruitment of PXR binding across the
genome following rifampin treatment. PXR-bound DNA frag-
ments clustered into 1,158 discrete peaks with DMSO treated cells
versus 6,302 after treatment with rifampin (Figure 1A, Table S2),
with only 239 overlapping in both datasets (Figure 1B). Rifampin
treatment led to a small increase in the percentage of promoters
(25.6% versus 24.1%) bound by PXR and a larger increase for
intronic (35.18% versus 29.9%) and exonic (5.3% versus 1.8%)
regions (Table S2). In contrast, there was a reduction in the
percentage of rifampin-induced PXR binding sites in intergenic
regions (33.9% versus 44.2%). An analysis of the location of
rifampin-induced PXR peaks found them to be enriched at
transcription start sites (TSSs), but not at a particular location
upstream or downstream to the TSS(Figure S1).
The binding of p300 was also more extensive after rifampin
treatment, with 13,811 peaks compared to 10,253 in DMSO-
treated cells (Figure 1A, Table S2). There was a larger overlap
between rifampin and DMSO treated ChIP-seq peaks compared
to PXR, with 4,374 (31.7%) in common between the two sets
(Figure 1B, Table S2). We also observed a change in the functional
distribution of binding sites, with rifampin increasing the
percentage of intronic (42.6% versus 36.3%) and intergenic
(38.0% versus 31.7%) p300 binding versus a small change in
exons (3.8% versus 2.6%) and a reduction in promoter binding
(15.5% versus 29.4%) (Table S2). This result was consistent with
our observation that only 1,076 rifampin-induced p300 peaks
overlapped rifampin-induced PXR peaks (Table S2).
In contrast to PXR and p300, the distribution of histone marks
was relatively stable, with about 49,000 enriched islands of
H3K4me1 activity and about 40,000 H3K27ac islands in both
treatments (Figure 1A). We also observed a large overlap between
rifampin and DMSO treated H3K4me1 (82.07%) and H3K27ac
(87.89%) enriched islands (Figure 1B, Table S2). Combined, these
results suggest that histone marks are more stable in response to
rifampin treatment compared to PXR and p300.
We next looked at overlaps between the different ChIP-seq
peaks. Amongst the 6,302 PXR rifampin treated peaks 1,037
(16%) overlapped p300 and around half overlapped histone marks
(3,553 for H3K27ac and 2,942 for H3K4me1). This was similar
for PXR peaks in the DMSO treated cells (Table S2). For p300 we
observed a greater overlap with histone marks, with ,70% of the
peaks overlapping either H3K27ac (9,487/13,811) and H3K4me1
(9,840/13,811). In the DMSO treated cells, we observed a much
higher overlap for p300 peaks with the active H3K27ac mark
(9,487/10,253; 92%) versus H3K4me1 (7,789/10,253; 76%),
suggesting that the p300 peaks in this condition tend to be in
active regions.
Functional validation of putative rifampin induced
promoters
There are multiple examples of promoter nucleotide variants
that are associated with inter-individual drug response
[4,5,13,38,39]. We thus sought to identify drug-dependent
promoters in our dataset which may harbor common variants
with novel effects on drug response. We selected 227 promoters for
200 genes (some genes had more than one promoter; Table S3)
from the LightSwitch Promoter Collection (SwitchGear Geno-
mics) for genes whose expression was induced by rifampin or
reside near rifampin-induced ChIP-seq peaks (Table S3). Of the
227 promoters, 154 overlap a PXR peak, 45 overlap p300, 164
overlap H3K27ac and 84 overlap H3K4me1 (Table S3). This
library consists of,1,000 bp proximal promoter fragments cloned
into pLightSwich_Prom vector (see Methods, Table S3). We also
included two positive controls: 1) The beta-actin promoter
(ACTB), a strong constitutive promoter that should not be induced
by rifampin and 2) The CYP3A4 proximal promoter, which is
known to be induced by rifampin. We tested the 227 promoters in
HepG2 cell lines co-transfected with human PXR and treated with
rifampin or vehicle control (DMSO). Out of the 227 tested
promoters, 179 were found to be functional promoters (.2 fold
luciferase activity above empty vector) in the DMSO treated cells
(Figure 2A, Table S3). Among those promoters, only 10 exhibited
.2 fold increase in promoter activity upon rifampin treatment
including our CYP3A4 proximal promoter control (Figure 2A). To
confirm that the effects of rifampin were mediated through PXR,
we also tested the 10 rifampin-induced promoters (including
CYP3A4) in a similar assay, only this time without co-transfecting
human PXR, and found only 2 of them to be induced by rifampin
(.2 fold increase in promoter activity upon rifampin treatment)
and at much lower levels (Figure 2B, Table S3). In addition, the
CYP3A4 promoter was also not induced by rifampin in this assay.
Figure 1. ChIP-seq summary. (A) Schematic of our RNA-seq and
ChIP-seq assays, showing the various antibodies used for ChIP-seq and
the total number of peaks obtained for each antibody and treatment.
(B) Overlap between DMSO and rifampin treated ChIP-seq peaks for
each antibody.
doi:10.1371/journal.pgen.1004648.g001
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In both experiments, our ACTB control was a strong promoter,
but not induced by rifampin. The overall lack of rifampin-sensitive
promoters and previous results finding a role for enhancers in
driving this drug response [24–27] suggests that other regulatory
sequences, such as enhancers, may be involved in driving the
effects of rifampin treatment on gene expression.
Rifampin induced regions reside near drug-associated
genes
Since most of the promoters tested in our assay did not
demonstrate increased activity in the presence of rifampin, we
broadened our search for inducible regulatory elements to include
enhancers. To be more stringent in our analyses, we selected
regions across the genome which showed PXR rifampin-induced
binding in addition to all three enhancer marks. For both the
DMSO and rifampin treatments, we generated a merged track of
all four marks, with each region in the track overlapping one to
four peaks/island. If, for example, a p300 peak is near a PXR
peak, but they don’t overlap, while both overlap a H3K4me1 and/
or a H3K27ac island, they were considered all as one region. Only
225 such regions were present in the DMSO treatment, while
1,387 were identified in the cells treated with rifampin (Figure 3A).
Of the latter group, 1,297 regions were exclusive to the rifampin
treatment and termed Rifampin-Induced Regions (RIRs) for
downstream analyses.
CYP3A4 is by far the most well studied target of PXR, with well
characterized regulatory sequences: the proximal promoter, a 2
7.5 kb upstream xenobiotic responsive enhancer module (XREM)
[24], and a211 kb constitutive liver enhancer module of CYP3A4
(CLEM4) [25]. A second potential XREM, putatively regulating
CYP3A7, was additionally identified intergenically between
CYP3A7 and CYP3A4 [26]. Our ChIP-seq data completely
recapitulates this picture of regulation in primary human
hepatocytes, with two large RIRs encompassing multiple rifam-
pin-induced peaks (Figure 3B). It is also worth noting that the
CYP3A4 locus is one of the few in which we observed a substantial
difference in rifampin-induced enrichment of the H3K4me1 and
H3K27ac marks.
To identify enriched biological pathways and functions within
the set of 1,297 RIRs, we carried out a genomic analysis using the
Genomic Regions Enrichment of Annotations Tool (GREAT
[40]). Our top enriched term (p-value 1.8561029; binominal fold
enrichment), originating from Pathway Commons (http://www.
pathwaycommons.org), was ‘xenobiotics’ (Figure 3C). This was
attributed to RIRs residing near the following genes: ABCB4,
ACSL1, ADH1A, ADH6, AKR1C2, AKR1C3, ALDH1A1,
CNDP2, CYP26A1, CYP2A6, CYP2B6, CYP2C19, CYP2C8,
CYP2C9, CYP2W1, CYP3A4, CYP3A7, CYP4F12, CYP4F3,
CYP7A1, GCLC, GCLM, GSTA2, GSTO1, GSTO2, HNF4A,
MAT1A, MAT2A, MGST2, MGST3, NCEH1, NNMT,
PAPSS2, PTGIS, SLC35D1, SULT1B1, SULT2A1, UGDH,
UGT1A1. In addition, we observed significant (FDR adjusted p-
value#0.05) gene ontology enrichment terms for drug catabolic
processes and other terms fitting with drug response (Figure 3C,
Table S4). We performed a similar analysis for RIR neighboring
genes using QIAGEN’s Ingenuity Pathway Analysis (IPA,
QIAGEN Redwood City, www.qiagen.com/ingenuity) and found
enrichment for the PXR/RXR Activation Canonical pathway
(Figure S2, Table S5). Combined, these results suggest that our
RIRs are enriched near drug-associated genes.
Functional validation of putative rifampin induced
enhancers
Although ChIP-seq is a valuable tool for the identification of
putative regulatory elements, functional studies are essential for
the validation of such sequences. We selected forty-nine putative
enhancer sequences for validation using two different selection
criteria: 1) Forty-two RIRs residing near drug-associated genes as
manually determined by the literature. 2) Seven rifampin-induced
PXR ChIP-seq peaks harboring SNPs that are in linkage
disequilibrium (LD) with pharmacogenomics or drug related
genome-wide association study (GWAS) lead SNPs, termed
GWAS linked peaks (GLPs) (Table S6). Previous studies have
shown that several GWAS SNPs reside near potential regulatory
elements that encompass SNPs that are in LD with the lead
GWAS SNP [41–43]. To increase our chances to identify these
Figure 2. Functional promoter assays. (A) From the 227 tested promoters (red dots), 179 were found to be functional promoters (.2 fold
luciferase activity above empty vector) in the DMSO treated cells (basal activity). Among those, 10 showed a .2-fold increase upon rifampin
treatment. (B) The 10 promoters exhibiting rifampin induction in A were tested again without PXR. Blue dots are the positive controls (ACTB and
CYP3A4 promoters) and the yellow dot is the empty vector.
doi:10.1371/journal.pgen.1004648.g002
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regulatory elements, we used our rifampin treated PXR-ChIP-seq
dataset, instead of the RIRs, since it had a larger number of peaks.
SNPs in LD with pharmacogenomics GWAS hits were signifi-
cantly enriched near rifampin-dependent PXR peaks compared to
SNPs in LD with non-pharmacogenomic GWAS hits (p,0.0001,
Chi-squared test). None of the sequences chosen overlapped
promoter regions (i.e. were within 22500/+500 bp of a TSS).
Candidate enhancer sequences were cloned into the pGL4.23
(Promega) enhancer assay vector, which contains a minimal
promoter followed by the luciferase reporter gene. Since the peaks
(or islands) enriched for the two histone marks are relatively long
(average length ,5 kb, Table S2), we selected shorter sequences
within each RIR that encompass only the PXR/p300 peaks along
with additional flanking sequence, up to 500 bp on each side of the
peak. We also used different positive controls: 1) The ApoE liver
enhancer [44] whose activity should not be enhanced by rifampin.
2) A CYP3A4 promoter-enhancer combination (p3A4-362(7836/
7208ins) [24] (Table S7) whose activity should be increased by
rifampin treatment. All constructs were tested for their enhancer
activity in HepG2 cells transfected with human PXR and treated
with either rifampin or DMSO, as previously done for the
promoter screen.
Out of the 49 sequences tested, 19 (38.7%) showed significant
reporter expression levels versus the empty vector ($2 two fold) in
either condition: 15 RIRs and 4 GLPs (Figure 4A, Table S7).
Among these 19 positive enhancers, we observed three types of
enhancers: 1) Seven enhancers that were active at similar levels
with DMSO and rifampin, termed ‘rifampin independent’. 2) Five
enhancers that were active without rifampin, but whose expression
levels significantly increased upon rifampin treatment, termed
‘rifampin increased’. 3) Seven enhancers that were active only
when treated with rifampin and were called ‘rifampin dependent’.
Two of these (GLP1 and GLP2) are located in the CYP2C locus
(Figure S3) and contain SNPs in LD with pharmacogenomics
GWAS SNPs for warfarin maintenance dose [45,46], acenocou-
marol maintenance dose [47] and response to clopidogrel therapy
[48]. Combined, these results show that enhancer activity can be
modulated by rifampin.
Genetic variants in enhancers drive differential
expression of PXR target genes and may explain
variability in drug response
We next determined whether common nucleotide variation
within functional, drug-dependent enhancers could alter their
activity. For these experiments we selected five enhancers that
were either rifampin increased or dependent and near important
drug-response genes. These included RIR7, which overlaps the
putative CYP3A7 XREM (Figure 3B; chr7: 99339411–99341549;
hg19) [26] and was rifampin dependent in our assays. We also
selected RIR46, which is located in the glutathione S-transferase
alpha (GSTA) locus near GSTA2 (chr6: 52609942–52611507;
hg19) (Figure S4) and was rifampin-increased in our assays. The
GSTA family of enzymes are known to be involved in the
metabolism of various xenobiotics [49]. We also selected three
different GLP sequences: GLP1, 2, and 5. Both GLP1
(chr10:96507473–96508107; hg19) and GLP2 (chr10:9669618
Figure 3. Genomic characterization of RIRs. (A) Overlap between
the four different ChIP-seq marks for DMSO and rifampin treated
human hepatocytes. Sequences having all four marks in the rifampin
treated datasets, were termed rifampin induced regions (RIRs). (B) The
CYP3A4 locus shows increased CYP3A4 expression in the rifampin
treated hepatocytes (red) versus DMSO treated cells (blue) as observed
through RNA-seq, as well as ChIP-based enrichment of PXR, p300,
H3K27ac and H3K4me1 in rifampin-(red) versus DMSO-treated cells
(blue). The xenobiotic responsive enhancer module (XREM) [24], the 2
11 kb constitutive liver enhancer module of CYP3A4 (CLEM4) [25] and
the CYP3A7 XREM [26] are also shown. RIRs are depicted as black lines
and the cloned RIR7 fragment as a black rectangle. (C) An analysis of
RIRs using GREAT [40] identified enriched biological processes
associated with drug response. Shown are only terms that have
binomial fold enrichment .6 and FDR adjusted P-values,561023. A
full listing can be seen in Table S4.
doi:10.1371/journal.pgen.1004648.g003
Drug-Dependent Liver Enhancers
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2–96696970; hg19) are located in the CYP2C locus (Figure S3),
which harbors several CYP metabolizing enzymes and has been
analyzed extensively in various pharmacogenomic studies. GLP5
(chr2:234672744–234673398; hg19) harbors a single SNP,
rs3771341, that is in LD with several GWAS lead SNPs correlated
with altered bilirubin levels [50–53] and was rifampin-increased in
our study. This element is located in the UDP glucuronosyl-
transferase 1 family, polypeptide A cluster (UGT1A), ,4 kb
upstream of the UGT1A1 transcription start site (Figure S5).
UGT1A enzymes have important roles in the metabolism of
xenobiotics and both coding and promoter variants within them
have been associated with adverse drug reactions [54].
We determined common haplotypes in all five sequences using
the phased 1000 Genomes data (Table S8). Common haplotypes
for all five sequences (Table S8) were then cloned into our
enhancer assay vector (pGL4.23) either by amplifying DNA from
individuals from various ethnic backgrounds from the studies of
pharmacogenomics in ethnically diverse populations (SOPHIE)
cohort [55] or by site-directed mutagenesis and sequence verified.
The sequences were then tested for enhancer activity in HepG2
cells transfected with human PXR and treated with either
rifampin or DMSO, and compared to the ancestral haplotype.
Out of the five tested enhancers, one haplotype in RIR46 showed
a substantial difference in enhancer activity. For RIR46, we
observed 1.85-fold (4.01/2.16) increase in response to rifampin for
haplotype 3, however after adjusting for multiple testing the
variance in the response was too high to be significant (adjusted p-
value = 0.095 by FDR; ANOVA; Figure 4B, Table S8). This
haplotype is present at a frequency of 6.7% in the 1000 Genomes
AFR population. It is worth noting that our success rate in finding
haplotypes that significantly alter enhancer activity was low.
Nonetheless, the observation that a haplotype in RIR46 could
possibly affect enhancer activity suggests that nucleotide variants
in these enhancers could lead to differential enhancer activity.
Discussion
By carrying out RNA-seq and ChIP-seq on rifampin and
DMSO treated human hepatocytes, we have uncovered numerous
drug-dependent regulatory elements. We observed that promoters
bearing a rifampin-dependent signature were largely unable to
independently induce the expression of a reporter upon rifampin
treatment. This result suggested that other gene regulatory
elements, such as enhancers, could constitute the predominant
group of target sequences that are activated by this drug. An
analysis of nucleotide variation in these enhancers showed that
specific variants could affect enhancer activity, raising the
possibility that nucleotide variants in enhancers could contribute
to pharmacogenomic phenotypes more broadly.
Our RNA-seq analyses that combined eight different individuals
identified 157 differentially expressed genes, using a p-value cutoff
that adjusted for multiple testing less than or equal to 0.05 (Table
S1). Many of these genes are known to be involved in drug
response and the top differentially expressed gene was CYP3A4,
fitting with its role as the most abundantly expressed gene in sites
of drug disposition in the liver [15]. The number of differentially
expressed genes (157), using our 0.05 cutoff, was much lower than
the number of RIRs (1,297) and PXR and p300 rifampin treated
ChIP-seq peaks. This difference could be attributed to having
multiple regulatory elements regulating the same gene. It could
also be due to our conservative RNA-seq differential expression
cutoff, which if relaxed would increase our gene list. Another cause
Figure 4. Functional enhancer assays. (A) RIRs or GLPs that showed positive enhancer activity in our assays. These were divided into three
classes: 1) rifampin independent, where the addition of rifampin did not change enhancer activity; 2) rifampin increased, where rifampin increased
enhancer activity; 3) rifampin dependent, when only upon rifampin treatment did the sequence show significant enhancer activity. An empty vector
was used as a negative control and the ApoE liver enhancer [44] and a CYP3A4 promoter-enhancer combination (p3A4-362(7836/7208ins) [24] labeled
as p3A4-36, were used as positive controls. (B) Haplotype 3 in RIR46 shows increased enhancer activity (adjusted p-value (FDR) = 0.095 from post test
when compared to the reference haplotype; one-way ANOVA).
doi:10.1371/journal.pgen.1004648.g004
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for this can be that several of our identified peaks are not
functional regulatory elements. Our functional characterization
for example, found only 19 of the 49 tested sequences (38.7%) to
have significant reporter expression levels versus the empty vector
($2 two fold). Of note though, that this could also be due to the
different cell types and conditions that were used in this assay, as
later described.
Similar studies have been conducted to detect environmentally
induced regulatory elements [28,56–59]. For example, testing for
changes in estrogen receptor a and RNA polymerase II occupancy
due to estradiol, tamoxifen or fulvestrant treatment in MCF-7
cells, found differences in ligand regulation with tamoxifen leading
to downregulation while fulvestrant increased RNAPII occupancy
[58]. In our study, we observed a large rifampin-induced
recruitment of PXR and p300 binding across the genome. This
was particularly notable in the CYP3A locus, which was radically
altered by rifampin treatment. For the most part, the regulatory
hotspots that we identified in this region are consistent with
established literature. It is worth noting, however, that we saw
almost equal recruitment of PXR and p300 to the XREMs that
putatively regulate CYP3A4 and CYP3A7, despite the fact that we
observed substantially less CYP3A7 mRNA induction by qPCR
and RNA-seq.
We did not observe large changes in the assayed histone marks,
H3K4me1 and H3K27ac. This could be attributed to these sites
being poised to be activated by various xenobiotic responses,
though H3K27ac has been previously shown to mark active
enhancers [34,35]. To get at these differences more systematically,
we performed a second analysis in which H3K4me1 and
H3K27ac peaks were called for the rifampin treatment using the
DMSO treatment as the control (Table S9). We observed 110
differential islands for H3K27ac, and only 2 for H3K4me1 (one of
which was in the CYP3A4 locus). The fact that we observed more
rifampin-induced peaks for H3K27ac is consistent with its
hypothesized role in marking active enhancers. Combined, these
results suggest that while these two marks are incredibly stable in
the face of massive changes in PXR/p300 binding, there are still
measurable drug-induced changes in chromatin structure.
Previous reports have found enhancers to be responders of drug
treatment [24–27]. Our functional validation results broadly
suggest that promoters on their own are largely incapable of
driving the effects of rifampin induction. Instead, our results imply
that enhancers appear to be induced by rifampin, and through
their interaction with promoters, drug response genes are
activated. We tested over 200 promoters of genes based on
relatively loose selection criteria: that their respective genes either
showed increased expression following rifampin treatment, were
tagged by our rifampin ChIP-seq peaks, or were near them. On
the other hand, for enhancers we required that candidates had all
four marks. While it is possible that our promoter selection criteria
missed out on important drug response promoters, we would still
expect to achieve a higher rifampin induction success rate than
what we observed in our assays (10/227; 4.4%). While our assays
may have not been ideal for these purposes, i.e. testing promoters
in vitro in PXR-transfected HepG2 cells, both our negative and
positive controls showed the expected results (Figure 2A).
Furthermore, rifampin-induced promoters tested in non-PXR
transfected conditions showed much lower induction by the drug
(Figure 2B). Further systematic assays including ones carried out
in vivo will be needed to better address this hypothesis.
While 12 out of the 19 functional sequences identified by our
screen exhibited basal enhancer activity, 7 sequences exhibited
enhancer activity only upon rifampin treatment (Figure 4A).
These sequences would not have been identified by conventional
ChIP studies conducted in physiological conditions, nor would
they be validated in functional assays without drug treatment.
Together our results suggest that ChIP-seq datasets are dependent
on the environmental conditions in which they were performed,
and that there are likely many hidden enhancers which only
become active following a specific stimulus.
We identified several functional enhancers that were rifampin-
increased or rifampin-induced whose location was near pharma-
cogenomic-associated variants. One of these elements is RIR46,
which resides near GSTA2, a Phase II enzyme involved in the
detoxification of numerous drugs [49], and is thus a likely target.
Coding variants in GSTA2 have been shown to affect its
detoxification efficiency [60,61] and promoter variants in GSTA2
have been suggested to affect its expression levels [62,63]. We
identified a haplotype present in the 1000 Genomes AFR
population that confers increased rifampin sensitivity (Figure 4B).
Both GSTA2 and GSTA1 (which is 28 kb downstream to
GSTA2), have been shown to have important roles in catalyzing
carcinogenic substrates and nucleotide variation in them has been
shown to be associated with cancer [60,64]. Previous work has
shown a significant difference in the distribution of coding SNPs in
both these genes between African Americans and Caucasians [60].
However, these coding SNPs are not associated with prostate
cancer disease status [60], suggesting that other factors could be
playing a role. Future studies could examine whether variants in
RIR46 or other RIRs are associated with these phenotypes.
It is worth noting that there are several caveats to our study.
Our ChIP-seq experiments only analyzed hepatocytes from a
single donor at a single time point (24 hours post treatment),
selected for being commonplace in rifampin induction studies. It is
possible that there are enhancers that play a role much earlier than
24 hours post-treatment. To test regulatory sequences in reporter
assays, it was also necessary to clone smaller fragments from each
RIR bearing the PXR and p300 peaks. It is possible that we
missed flanking sequences that were essential for enhancer
function. Furthermore, because we had a limited amount of
primary hepatocytes from the same donor, our reporter assays
were carried out in PXR-transfected HepG2 cells, which could
result in false negatives. Finally, we employed the pGL4.23 vector,
which is a commonly used enhancer assay vector, but possesses a
very short TATA-box containing minimal promoter that may not
be compatible with all of the enhancer sequences tested.
Promoter regions upstream of drug metabolizing enzymes and
transporters are presumed to be the major targets of xenobiotic
activators of PXR, such as rifampin. Our work challenges this
conception and strongly supports the idea that the direct targets
could be enhancer elements, which may subsequently interact with
promoters to enhance gene transcription. Combined, our results
show that ChIP-seq in combination with drug treatment has a
large potential in identifying novel regions in the genome
associated with drug response. These regions can provide
exceptional candidates for the detection of nucleotide variants
associated with inter-individual differences in drug response. Our
methodology could easily be adapted to other drugs/target/tissue
combinations. With whole genome datasets becoming more widely
used as a clinical toolbox, the ability to highlight these important
drug response regions in the genome is of extreme importance.
Materials and Methods
Primary hepatocyte culture
Cryopreserved human hepatocytes from a 19 year old
Caucasian male donor with no history of medications (Lot
Hu8080, Life Technologies) were thawed in CHRM recovery
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media (Cat# CM7000, Life Technologies) and cultured in CHPM
plating media (Cat#CM9000, Life Technologies) on 6-well
collagen-coated plates (Life Technologies). After 6 hours, the
media was swapped with maintenance media, consisting of
phenol-free Williams E media containing culture incubation
supplements (Cat#CM4000, Life Technologies) and 0.01%
DMSO or 10 mM rifampin (Sigma) for 24 hours. The rifampin
dose (10 mM for 24 hours) was used based on previously reported
assays achieving high induction rates in human hepatocytes
[65,66]. Dexamethasone, which is included separately with the
culture incubation supplements, was not added to the media as it
can activate PXR.
Quantitative PCR validation
Cultured hepatocytes were treated with DMSO or rifampin for
24 hours in triplicate. The cells were then washed with PBS, and
lysed directly with Buffer RLT from the RNAeasy mini kit
(Qiagen) with the on-column DNase digestion step. One mg of
total RNA was used to generate cDNA using the RT2 First Strand
Kit (Qiagen). Gene expression levels for 84 genes of interest was
determined using the ‘‘Drug Metabolism: Phase I Enzymes’’ RT2
Profiler PCR Array (Qiagen). Five housekeeping genes (B2M,
HPRT1, RPL13A, GAPDH, ACTB) were used to control for
loading. Fold induction was calculated using the DDCt method
[67].
RNA-seq
Total RNA was acquired as described for qPCR for two
replicates each of DMSO and rifampin treated hepatocytes.
Libraries were made with ScriptSeq v2 RNA-Seq Library
Preparation Kit (Epicenter). Briefly, 3–5 ug of total RNA were
subjected to rRNA removal using Ribo-Zero Magnetic Kit
(Epicenter) prior to library construction. 5 ng of the rRNA-
depleted sample was fragmented enzymatically and annealed with
random hexamer to create the first strand of cDNA. Upon
removal of the RNA template transcript by RNase, Terminal-
Tagging Oligo (TTO), a known 59-sequence tag, a 39-random
sequence, and a terminally blocked 39 end to prevent priming of
DNA synthesis, was added to create cDNA with known sequence
tags at their 59 and 39 ends for directionality. Upon purification,
adaptors with barcodes were added to cDNA fragments and
enriched by 15 cycles of PCR. Sequencing was carried out on an
Illumina HiSeq. The resulting reads were demultiplexed and
aligned to the human genome (hg19) using TopHat v2.0.10 [68].
Read counts for each gene in the RefSeq annotation were
obtained using NGSUtils [69] so as to allow comparison to the
RNA-seq data from the other 7 primary hepatocytes treated with
and without rifampin and sequenced with SOLiD as described in
[37]. Analysis for differential expression across the nine replicates
was performed using DESeq2 [70]. DESeq2 was chosen due to its
capability in handling multifactorial experimental designs, in this
case treated with rifampin versus control and SOLiD sequences
versus Illumina. DESeq2 was then used to perform a likelihood
ratio test between the model of treatment plus sequencing type
versus the simplified model of just sequencing type in order to
identify genes differentially expressed upon treatment with
rifampin.
ChIP-seq
Twelve million cells (an entire 6 well plate) per immunoprecip-
itation were fixed with 1% formaldehyde for 15 min and
quenched with 0.125 M glycine. The remainder of the ChIP-seq
protocol was carried out by Active Motif Inc., as follows.
Chromatin was isolated by adding lysis buffer, followed by
disruption with a Dounce homogenizer. Lysates were sonicated
and the DNA sheared to an average length of 300–500 bp.
Genomic DNA (Input) was prepared by treating aliquots of
chromatin with RNase, proteinase K and heat for de-crosslinking,
followed by ethanol precipitation. Pellets were resuspended and
the resulting DNA was quantified on a NanoDrop spectropho-
tometer. Extrapolation to the original chromatin volume allowed
quantitation of the total chromatin yield.
An aliquot of chromatin (30 ug) was pre-cleared with protein G
agarose beads (Invitrogen). Genomic DNA regions of interest were
isolated using 4 ug of antibody against PXR (sc-25381, Santa
Cruz), 4 ug of antibody against p300 (Cat#sc-595, Santa Cruz),
20 ug of antibody against H3K27ac (Cat#ab4729, Abcam) and
5 ug antibody against H3K4me1 (Cat#ab8895, Abcam). Due to
the limited amount of cryopreserved human hepatocytes from this
donor, we elected to do various enhancer-associated ChIP-seq
marks instead of additional replicates. Complexes were washed,
eluted from the beads with SDS buffer, and subjected to RNase
and proteinase K treatment. Crosslinks were reversed by
incubation overnight at 65 C, and ChIP DNA was purified by
phenol-chloroform extraction and ethanol precipitation.
ChIP and input DNAs were prepared for amplification by
converting overhangs into phosphorylated blunt ends and adding
an adenine to the 39 ends. Illumina adaptors were added and the
library was size-selected (175–225 bp) on an agarose gel. The
adaptor-ligated libraries were amplified for 18 cycles. The
resulting amplified DNAs were purified, quantified, and tested
by qPCR at the same specific genomic regions as the original ChIP
DNA to assess quality of the amplification reactions. Amplified
DNA libraries were sequenced on the Illumina Genome Analyzer
II.
The 36-nt sequence reads identified by the Sequencing Service
were mapped to the genome using the ELAND (Illumina). Default
settings were used: only tags that map uniquely, have no more
than 2 mismatches, and that pass quality control filtering were
considered.
PXR and p300 peaks were called against input using MACS
version 1.4 [71] and for H3K27ac and H3K4me1 using SICER
version 1.1 [72]. A p-value cutoff of 161027 was used for MACS
and an FDR of 0.01% was used as a cutoff for SICER, and the
remaining parameters set to the default. For the alternate analysis
presented in Table S9, we used a more stringent threshold in
SICER of 1610210.
For the analysis of the distribution of PXR ChIP-seq peaks
following rifampin treatment, we used knownGene from the
UCSC Genome Browser to define the transcription start site (TSS)
as the center and pybedtools [73] for the calculations followed by
matplotlib (http://matplotlib.org) to plot.
Reporter plasmids
Selected promoters were obtained from the LightSwitch
Promoter Collection (SwitchGear Genomics) and sequence
verified in the pLightSwitch_Prom vector. Candidate enhancers
were amplified from human genomic DNA (Roche) using
oligonucleotides designed in Primer3 with 16 bp overhangs (59-
GCTCGCTAGCCTCGAG-39 and 59CGCCGAGGCCAGAT-
CT-39) complementary to the sequence flanking the BglII and
XhoI sites in the pGL4.23 vector (Promega). Primers were
designed to encompass the PXR/p300 ChIP-seq peak plus up to
500 bp of sequence on either side of the peak. PCR products were
cleaned using the QIAquick PCR Purification Kit (Qiagen) and
cloned into BglII and XhoI digested pGL4.23 using the Infusion
HD cloning system (Clontech). Haplotypes were generated either
by PCR amplification of DNA from various ethnic individuals or
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by site-directed mutagenesis using mutant primers amplified by
PfuUltra High Fidelity DNA polymerase (Agilent) followed by
DpnI digestion of the parental DNA (New England Biolabs) and
transformation into competent cells. Sequences were verified by
Sanger sequencing using RVPrimer3 (59-CTAGCAAAATAG-
fGCTGTCCC-39) and a custom reverse primer (59-TCT-
TCCATGGTGGCTTTACC-39).
Identification of GWAS-associated PXR peaks
We manually curated the NHGRI GWAS catalog [74], dated
December 15th, 2011, to identify 397 SNPs from 92 pharmaco-
genomic GWAS studies. Using data from the 1000 Genomes
March 2012 Interim release (http://1000genomes.org), we iden-
tified a larger set of SNPs in linkage disequilibrium with those
SNPs (r2.0.8) in the race/ethnicity corresponding to the
pharmacogenetics study. Ten rifampin-induced PXR peaks
overlapped at least one of these GWAS-LD SNPs (Table S6)
and seven were selected for functional enhancer assays. To
determine enrichment, we compared overlap of the LD blocks
defined by the 397 lead SNPs from pharmacogenomic GWAS to
5,117 lead SNPs from non-pharmacogenomic GWAS. These
assignments were curated manually. Each list of SNPs was
intersected with the 6,302 rifampin-induced PXR peaks, resulting
in 27 and 162 overlapping SNPs respectively. Using a two-tailed
Chi-squared test with Yates’ correction, we found the enrichment
to be highly significant (p,0.0001).
Luciferase reporter assays
HepG2 cells (ATCC) were maintained in D-MEM (Life
Technologies) supplemented with FBS (JRS Scientific), Penicil-
lin-Streptomycin and Glutamine (UCSF Cell Culture Facility). On
the day of transfection, the cells were trypsinized, washed, and
diluted to a density of 1 million cells/ml in Opti-MEM I Reduced
Serum Media (Life Technologies). Ninety thousand cells and
125,000 cells were added to each well of a 96-well clear bottom
black tissue culture plate (Greiner Bio-One) containing the
transfection mixture for the promoter and enhancer assay
respectively. The transfection mixture consisted of 50 ng of
human PXR (PXR cDNA cloned into the pcDNA3.1(+) vector),
10 ng of pGL4.74, 21.5 ul Opti-MEM, 100 ng of reporter
construct, and 0.48 ul of Lipofectamine LTX reagent (Life
Technologies). After 18 hours of incubation at 37 degrees Celsius,
the cells were washed with 150 ul Opti-MEM and the media was
replaced with 100 ul of Opti-MEM supplemented with 10 uM
Rifampin or 0.1% DMSO. After 24 hours of incubation, the cells
were washed with PBS and the promoter assay cells were placed at
280 degrees Celsius for 30 minutes to lyse and the enhancer
assayed cells were lysed with 25 ul of Passive Lysis Buffer
(Promega). All LightSwitch promoter vectors were measured with
the LightSwitch Luciferase Assay reagents (SwitchGear Genomics)
following the manufacturers protocol. For enhancers, reporter
activity was measured using the Dual-Luciferase Reporter Assay
System (Promega). Both assays were measured on a microplate
luminometer (Promega).
Identification of common haplotypes from 1000
Genomes data
We used the 1000 Genomes March 2012 Interim release (),
which contained genotypes for 379 White, 286 Asian, 181 Latino,
and 246 African race/ethnicity individuals. For each gene RIR/
GLP region, we identified haplotypes determined by computa-
tionally phasing the SNPs in the program PLINK v1.07 [75],
again using the corresponding race/ethnicity.
Accession numbers
ChIP-seq and RNA-seq data has been made publically available
through NCBI (ChIP-seq BioProject ID: PRJNA239635; RNA-
seq BioProject ID: PRJNA239637).
Supporting Information
Figure S1 Distribution of PXR ChIP-seq peaks following
rifampin treatment. (A) All genes. (B) Differentially expressed
genes only.
(PDF)
Figure S2 Ingenuity Pathway Analysis of genes near rifampin
induced regions (RIRs) shows genes involved in ‘‘PXR/RXR
Activation’’. Upregulated genes are colored in red and
downregulated genes are colored in green as determined
through either qPCR or RNA-seq. Fold differences are shown
as a log2 ratio below each one of the differentially expressed
genes. CYP2A6* represents the CYP2A13 gene which is
upregulated.
(PDF)
Figure S3 GLP1 and GLP2. (A)CYP2C locus showing both the
RNA-seq and ChIP-seq results for DMSO (blue) and rifampin
(red) treated hepatocytes. GLP1 and GLP2 are depicted by green
lines above the CYP2C genes. (B) Common SNPs in GLP1 and
GLP2.
(TIF)
Figure S4 GSTA locus showing both the RNA-seq and ChIP-
seq results for DMSO (blue) and rifampin (red) treated
hepatocytes. The cloned RIR46 fragment is depicted by a black
rectangle upstream to GSTA2.
(TIF)
Figure S5 GLP5. (A)UGT1A locus showing both the RNA-seq
and ChIP-seq results for DMSO (blue) and rifampin (red) treated
hepatocytes. GLP5 is depicted by a green line above the UGT1A
genes. (B) The location of common SNPs within GLP5.
(TIF)
Table S1 qPCR results for 84 genes known to be involved in
drug response and RNA-seq results following vehicle or rifampin
treatment.
(XLSX)
Table S2 ChIP-seq summary.
(XLSX)
Table S3 Promoter assay results.
(XLSX)
Table S4 GREAT analysis of rifampin induced regions (RIRs).
(XLSX)
Table S5 Ingenuity Pathway Analysis of genes near rifampin
induced regions (RIRs).
(XLS)
Table S6 GWAS linked peaks (GLPs).
(XLSX)
Table S7 Enhancer assay results.
(XLSX)
Table S8 The various common haplotypes selected for differ-
ential enhancer assays, haplotype enhancer assays results and
ANOVA analyses.
(XLSX)
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Table S9 H3K4me1 and H3K27ac islands identified by
alternate analysis in which the rifampin-treated sample was
compared directly to the DMSO treatment as reference.
(XLSX)
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